Navidea sponsors research at Penn to evaluate Tc99m tilmanocept as prognostic marker in glioblastoma Feb. 8, 2022
Dyve and Moffitt collaborate to study buffering agent for transdermal delivery in cancer models Feb. 7, 2022
Parkinson's UK and Domainex collaborate to target neuroinflammation to slow Parkinson's disease Feb. 7, 2022
eTheRNA and Merck KGaA sign research agreement to assess mRNA technology for therapeutic vaccination Feb. 7, 2022
LISCure and Scripps collaborate on bacteria-mediated immuno-oncology candidates for cancer Feb. 4, 2022
Brickell licenses rights to Carna's STING antagonists for autoimmune and inflammatory diseases Feb. 3, 2022
Edigene, Haihe Lab co-develop hematopoietic stem cell regenerative therapies Feb. 1, 2022 By Doris Yu Edigene Inc. has extended a long-running partnership with an academic lab at the Chinese Academy of Medical Sciences and Peking Union Medical College with the goal of co-developing hematopoietic stem cell regenerative therapies and technology.Read More
RSS